December 13, 2018

What can we gain from looking at the outliers?: An investigation into long and short-term ovarian cancer survivors

Kayla Marsh, a Research Technician, wiorks at a bench in the OICR-PM Translational Genomics Laboratory.

Researchers investigate the clinical, molecular and microenvironment factors that contribute to extreme therapy response and resistance in ovarian cancer patients

Some patients with high-grade serous ovarian cancer (HGSOC) respond exceptionally well to therapy, while others experience rapid disease relapse. The mechanisms behind these disparate outcomes are poorly understood, but a group of researchers based at the Princess Margaret Cancer Centre (PM) supported by OICR’s Ovarian Cancer Translational Research Initiative (TRI) are working to change that.

Continue reading – What can we gain from looking at the outliers?: An investigation into long and short-term ovarian cancer survivors

November 6, 2018

Discovering new ways to deploy the immune system against hidden cancers

Superresolution image of a group of killer T cells (green and red) surrounding a cancer cell (blue, center). When a killer T cell makes contact with a target cell, the killer cell attaches and spreads over the dangerous target. The killer cell then uses special chemicals housed in vesicles (red) to deliver the killing blow.

Researchers studying ovarian cancer identify adapter protein 3BP2 as a key component of immune system function and a powerful tool that could be used to activate the immune system against hidden tumour cells.

Continue reading – Discovering new ways to deploy the immune system against hidden cancers